Hypermethylation of CpG islands and shores around specific MicroRNAs and mirtrons is associated with the phenotype and presence of bladder cancer

Clinical Cancer Research

Volumn 17, Issue 6, 2011, Pages 1287-1296

  Dudziec, Ewa ^a   Miah, Saiful ^a   Choudhry, Hani M Z ^a   Owen, Helen C ^a,b   Blizard, Sheila ^a   Glover, Maggie ^a   Hamdy, Freddie C ^c   Catto, James W F ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b UNIVERSITY OF LEUVEN   (Belgium)

^c UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

MICRORNA; MIRTRON; RNA; UNCLASSIFIED DRUG;

ARTICLE; CANCER GRADING; CANCER STAGING; CONTROLLED STUDY; CPG ISLAND; CPG SHORE; DISEASE ASSOCIATION; DISEASE MARKER; DNA METHYLATION; DNA STRUCTURE; EPIGENETICS; GENE EXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; TRANSITIONAL CELL CARCINOMA; UROTHELIUM;

AZACITIDINE; COHORT STUDIES; CPG ISLANDS; DNA METHYLATION; EPIGENESIS, GENETIC; EXONS; GENE SILENCING; HUMANS; ODDS RATIO; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PHENOTYPE; PROGNOSIS; URINARY BLADDER NEOPLASMS; UROTHELIUM;

EID: 79952727299     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-10-2017     Document Type: Article

References (38)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics 2009. CA Cancer J Clin 2009;59:225-49.
2. Knowles MA. Molecular subtypes of bladder cancer: Jekyll and Hyde or chalk and cheese?Carcinogenesis 2006;27:361-73.
3. Lindgren D, Frigyesi A, Gudjonsson S, Sjodahl G, Hallden C, Chebil G, et al. Combined gene expression and genomic profiling define two intrinsic molecular subtypes of urothelial carcinoma and gene signatures for molecular grading and outcome. Cancer Res 2010;70:3463-72.
4. Catto JW, Azzouzi AR, Rehman I, Feeley KM, Cross SS, Amira N, et al. Promoter hypermethylation is associated with tumor location, stage, and subsequent progression in transitional cell carcinoma. J Clin Oncol 2005;23:2903-10. (Pubitemid 46224108)
5. Yates DR, Rehman I, Abbod MF, Meuth M, Cross SS, Linkens DA, et al. Promoter hypermethylation identifies progression risk in bladder cancer. Clin Cancer Res 2007;13:2046-53. (Pubitemid 46649871)
6. Croce CM. Causes and consequences of microRNA dysregulation in cancer. Nat Rev Cancer 2009;10:704-14.
7. Catto JW, Miah S, Owen HC, Bryant H, Dudziec E, Larre S, et al. Distinct microRNA alterations characterize high and low grade bladder cancer. Cancer Res 2009;69:8472-81.
8. Saito Y, Liang G, Egger G, Friedman JM, Chuang JC, Coetzee GA, et al. Specific activation of microRNA-127 with downregulation of the proto-oncogene BCL6 by chromatin-modifying drugs in human cancer cells. Cancer Cell 2006;9:435-43. (Pubitemid 43832188)
9. Yates DR, Rehman I, Meuth M, Cross SS, Hamdy FC, Catto JW. Methylational urinalysis: a prospective study of bladder cancer patients and age stratified benign controls. Oncogene 2006;25:1984-8.
10. Irizarry RA, Ladd-Acosta C, Wen B, Wu Z, Montano C, Onyango P, et al. The human colon cancer methylome shows similar hypo- and hypermethylation at conserved tissue-specific CpG island shores. Nat Genetics 2009;41:178-86.
11. Lujambio A, Ropero S, Ballestar E, Fraga MF, Cerrato C, Setien F, et al. Genetic unmasking of an epigenetically silenced microRNA in human cancer cells. Cancer Res 2007;67:1424-9. (Pubitemid 46383366)
12. Lujambio A, Calin GA, Villanueva A, Ropero S, Sanchez-Cespedes M, Blanco D, et al. A microRNA DNA methylation signature for human cancer metastasis. Proc Natl Acad Sci U S A 2008;105:13556-61.
13. Lehmann U, Hasemeier B, Christgen M, Muller M, Romermann D, Langer F, et al. Epigenetic inactivation of microRNA gene hsa-mir-9-1 in human breast cancer. J Pathol 2008;214:17-24.
14. Ruby JG, Jan CH, Bartel DP. Intronic microRNA precursors that bypass Drosha processing. Nature 2007;448:83-6. (Pubitemid 47037009)
15. Okamura K, Hagen JW, Duan H, Tyler DM, Lai EC. The mirtron pathway generates microRNA-class regulatory RNAs in Drosophila. Cell 2007;130:89-100. (Pubitemid 47031325)
16. Southgate J, Hutton KA, Thomas DF, Trejdosiewicz LK. Normal human urothelial cells in vitro: proliferation and induction of stratification. Lab Invest 1994;71:583-94. (Pubitemid 24338167)
17. Choudhry H, Catto JW. Epigenetic regulation of microRNA expression in cancer. Methods Mol Biol 2010;676:165-84.
18. Dhawan D, Hamdy FC, Rehman I, Patterson J, Cross SS, Feeley KM, et al. Evidence for the early onset of aberrant promoter methylation in urothelial carcinoma. J Pathol 2006;209:336-43. (Pubitemid 43997742)
19. Catto JW, Hartmann A, Stoehr R, Bolderson E, Rehman I, Rosario DJ, et al. Multifocal urothelial cancers with the mutator phenotype are of monoclonal origin and require panurothelial treatment for tumor clearance. J Urol 2006;175:2323-30. (Pubitemid 43668524)
20. Gardiner-Garden M, Frommer M. CpG islands in vertebrate genomes. J Mol Biol 1987;196:261-82. (Pubitemid 17122132)
21. Megraw M, Sethupathy P, Corda B, Hatzigeorgiou AG. miRGen: a database for the study of animal microRNA genomic organization and function. Nucl Acids Res 2007;35:D149-55.
22. Berezikov E, Chung WJ, Willis J, Cuppen E, Lai EC. Mammalian mirtron genes. Mol Cell 2007;28:328-36. (Pubitemid 47600007)
23. Novak P, Jensen TJ, Garbe JC, Stampfer MR, Futscher BW. Stepwise DNA methylation changes are linked to escape from defined proliferation barriers and mammary epithelial cell immortalization. Cancer Res 2009;69:5251-8.
24. Kimura F, Florl AR, Seifert HH, Louhelainen J, Maas S, Knowles MA, et al. Destabilization of chromosome 9 in transitional cell carcinoma of the urinary bladder. Br J Cancer 2001;85:1887-93. (Pubitemid 34775326)
25. Mishra PJ, Song B, Mishra PJ, Wang Y, Humeniuk R, Banerjee D, et al. MiR-24 tumor suppressor activity is regulated independent of p53 and through a target site polymorphism. PLoS One 2009;4:e8445.
26. Wiklund ED, Bramsen JB, Hulf T, Dyrskjot L, Ramanathan R, Hansen TB, et al. Coordinated epigenetic repression of the miR-200 family and miR-205 in invasive bladder cancer. Int J Cancer 2010;128:1327-34.
27. Furuta M, Kozaki KI, Tanaka S, Arii S, Imoto I, Inazawa J. miR-124 and miR-203 are epigenetically silenced tumor-suppressive microRNAs in hepatocellular carcinoma. Carcinogenesis 2009;31:766-76.
28. Lodygin D, Tarasov V, Epanchintsev A, Berking C, Knyazeva T, Korner H, et al. Inactivation of miR-34a by aberrant CpG methylation in multiple types of cancer. Cell Cycle 2008;7:2591-600.
29. Hu X, Schwarz JK, Lewis JS Jr, Huettner PC, Rader JS, Deasy JO, et al. A microRNA expression signature for cervical cancer prognosis. Cancer Res 2010;70:1441-8.
30. Martin R, Smibert P, Yalcin A, Tyler DM, Schafer U, Tuschl T, et al. A Drosophila pasha mutant distinguishes the canonical microRNA and mirtron pathways. Mol Cell Biol 2009;29:861-70.
31. Urist MJ, Di Como CJ, Lu ML, Charytonowicz E, Verbel D, Crum CP, et al. Loss of p63 expression is associated with tumor progression in bladder cancer. Am J Pathol 2002;161:1199-206.
32. Tai AL, Mak W, Ng PK, Chua DT, Ng MY, Fu L, et al. High-throughput loss-of-heterozygosity study of chromosome 3p in lung cancer using single-nucleotide polymorphism markers. Cancer Res 2006;66:4133-8.
33. Nymark P, Wikman H, Ruosaari S, Hollmen J, Vanhala E, Karjalainen A, et al. Identification of specific gene copy number changes in asbestos-related lung cancer. Cancer Res 2006;66:5737-43. (Pubitemid 43927127)
34. Marsit CJ, Hasegawa M, Hirao T, Kim DH, Aldape K, Hinds PW, et al. Loss of heterozygosity of chromosome 3p21 is associated with mutant TP53 and better patient survival in non-small-cell lung cancer. Cancer Res 2004;64:8702-7. (Pubitemid 39552086)
35. Staub E, Grone J, Mennerich D, Ropcke S, Klamann I, Hinzmann B, et al. A genome-wide map of aberrantly expressed chromosomal islands in colorectal cancer. Mol Cancer 2006;5:37.
36. Knowles MA, Elder PA, Williamson M, Cairns JP, Shaw ME, Law MG. Allelotype of human bladder cancer. Cancer Res 1994;54:531-8. (Pubitemid 24053197)
37. Kudo T, Nakagawa H, Takahashi M, Hamaguchi J, Kamiyama N, Yokoo H, et al. N-glycan alterations are associated with drug resistance in human hepatocellular carcinoma. Mol Cancer 2007;6:32.
38. Ide Y, Miyoshi E, Nakagawa T, Gu J, Tanemura M, Nishida T, et al. Aberrant expression of N-acetylglucosaminyltransferase-IVa and IVb (GnT-IVa and b) in pancreatic cancer. Biochem Biophys Res Commun 2006;341:478-82. (Pubitemid 43152129)